within Pharmacolibrary.Drugs.ATC.L;

model L01ED03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.37,
    Cl             = 0.0013650000000000001,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.475,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0017,
    Tlag           = 51.0,            
    Vdp             = 1.78,
    k12             = 358,
    k21             = 358
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01ED03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Alectinib is an orally active, highly selective, and potent anaplastic lymphoma kinase (ALK) inhibitor used mainly in the treatment of ALK-positive non-small cell lung cancer (NSCLC). It is approved by regulatory agencies including the FDA and EMA for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with ALK-positive non-small cell lung cancer under fasted or fed conditions.</p><h4>References</h4><ol><li><p>Paik, J, &amp; Dhillon, S (2018). Alectinib: A Review in Advanced, ALK-Positive NSCLC. <i>Drugs</i> 78(12) 1247–1257. DOI:<a href=\"https://doi.org/10.1007/s40265-018-0952-0\">10.1007/s40265-018-0952-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30030733/\">https://pubmed.ncbi.nlm.nih.gov/30030733</a></p></li><li><p>Liu, SN, et al., &amp; Miles, D (2023). Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling. <i>Clinical and translational science</i> 16(6) 1085–1096. DOI:<a href=\"https://doi.org/10.1111/cts.13515\">10.1111/cts.13515</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36978270/\">https://pubmed.ncbi.nlm.nih.gov/36978270</a></p></li><li><p>Ren, C, et al., &amp; Jiang, B (2021). Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib. <i>European journal of medicinal chemistry</i> 217 113335–None. DOI:<a href=\"https://doi.org/10.1016/j.ejmech.2021.113335\">10.1016/j.ejmech.2021.113335</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33751979/\">https://pubmed.ncbi.nlm.nih.gov/33751979</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01ED03;
